Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2017-03-20 Capital/Financing Update
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
AURINIA PHARMACEUTICALS INC. 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a news release about closing a public offering of common shares and the exercise of underwriters' option. The document length is 2387 characters, which is relatively short and primarily serves as an announcement of a financing event rather than a full financial report. The key content is about a capital raising transaction (public offering of shares). Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2017-03-20 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The text includes a news release about a presentation at international congresses, but the document itself is a regulatory filing submitted to the SEC. The length is 2377 characters, which is relatively short and does not contain detailed financial statements or substantive financial data. It mainly serves as a regulatory announcement and includes an exhibit index referencing a news release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and filing that does not fit other specific categories.
2017-03-16 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Aurinia Pharmaceuticals Inc., pursuant to SEC rules under the Securities Exchange Act of 1934. It includes an exhibit which is an Underwriting Agreement dated March 14, 2017. The document length is 2108 characters, which is relatively short and primarily serves as a regulatory filing to report material information between annual reports. There is no detailed financial data, management discussion, or earnings information present. The document is not an annual report, earnings release, or any detailed financial report but rather a regulatory disclosure filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-03-16 English
SUPPL
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Form F-10, related to a short form base shelf prospectus. It details an offering of common shares by Aurinia Pharmaceuticals Inc., including underwriting agreements, pricing, and share allocation. The content focuses on the terms and conditions of a securities offering, underwriting fees, risk factors, and legal considerations. There is no indication of financial statements, management discussion, earnings data, or regulatory certifications. The document is clearly a capital raising disclosure, specifically a prospectus supplement for a public offering of shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual offering document, not just an announcement or a brief summary.
2017-03-14 English
AURINIA PHARMACEUTICALS INC. 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The text includes a news release about pricing a public offering of common shares. The document length is 2308 characters, which is relatively short and primarily serves as an announcement rather than a full financial report. The key content is about a financing event (public offering of shares). According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, this document is best classified as a Capital/Financing Update (CAP).
2017-03-14 English
FWP
Capital/Financing Update Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' and references a Registration Statement on Form F-10 and a Preliminary Prospectus Supplement. It discusses details about the offering documents, delivery of shares, settlement dates, and contact information for obtaining prospectus supplements. The content is focused on securities offering and fundraising activities, specifically related to a prospectus supplement and registration statement filings. There is no financial performance data, earnings information, or management discussion. The document is clearly related to capital raising and financing activities. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length is short (3050 characters), but it contains substantive information about the offering, not just an announcement of a report, so it is not an RPA or RNS.
2017-03-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.